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HM Highland1, JD Stewart1,13, TB Harris14, S Trompet5,15, JC Bis3, GM Peloso10, JA Brody3, L Broer16, EL Busch17,18, Q Duan19, AM Stilp6,
CJ O’Donnell20,21,22, PW Macfarlane23, JS Floyd3,24, JA Kors25, HJ Lin8,26, R Li-Gao27, T Sofer3, R Méndez-Giráldez1, SR Cummings9,
SR Heckbert24, A Hofman4, I Ford28, Y Li19,29,30, LJ Launer14, K Porthan31, C Newton-Cheh23,32,33,34, MD Napier1, KF Kerr6, AP Reiner24,35,
KM Rice6, J Roach36, BM Buckley37, EZ Soliman38, R de Mutsert27, N Sotoodehnia24,39,40, AG Uitterlinden16, KE North1, CR Lee41,
V Gudnason42,43, T Stürmer1,44, FR Rosendaal27, KD Taylor8, KL Wiggins3, JG Wilson45, Y-DI Chen8, RC Kaplan46, K Wilhelmsen19,47,
LA Cupples10,21, V Salomaa11, C van Duijn4, JW Jukema15,48,49, Y Liu50, DO Mook-Kanamori27,51,52, LA Lange19, RS Vasan21,53,
AV Smith42,43, BH Stricker4,54, CC Laurie6, JI Rotter8, EA Whitsel1,55, BM Psaty3,24,56,57 and CL Avery1,13
Thiazide diuretics, commonly used antihypertensives, may cause QT interval (QT) prolongation, a risk factor for highly fatal and
difficult to predict ventricular arrhythmias. We examined whether common single-nucleotide polymorphisms (SNPs) modified the
association between thiazide use and QT or its component parts (QRS interval, JT interval) by performing ancestry-specific, trans-
ethnic and cross-phenotype genome-wide analyses of European (66%), African American (15%) and Hispanic (19%) populations
(N= 78 199), leveraging longitudinal data, incorporating corrected standard errors to account for underestimation of interaction
estimate variances and evaluating evidence for pathway enrichment. Although no loci achieved genome-wide significance
(Po5 × 10− 8), we found suggestive evidence (Po5 × 10− 6) for SNPs modifying the thiazide-QT association at 22 loci, including ion
transport loci (for example, NELL1, KCNQ3). The biologic plausibility of our suggestive results and simulations demonstrating modest
power to detect interaction effects at genome-wide significant levels indicate that larger studies and innovative statistical methods
are warranted in future efforts evaluating thiazide–SNP interactions.
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INTRODUCTION
Over the past decade, the use of prescription drugs has
skyrocketed, with nearly half of all Americans now taking at least
one prescription drug.1 Accompanying the increased prevalence
of drug use is a high burden of adverse drug reactions (ADRs),
which account for approximately 100 000 deaths and 2.2 million
serious health effects annually.2–4 QT interval (QT) prolongation,
which can trigger fatal ventricular arrhythmias, is a long-
recognized adverse effect5 of numerous common medications,
such as antipsychotics, antibiotics, antiarrhythmics and
antihypertensives.6 Within the past ten years, QT prolongation
has represented the most common cause for withdrawal of a drug
from the market (or relabeling) after approval by the US Food and
Drug Administration (FDA).7,8 However, drug-induced QT prolon-
gation remains difficult to predict.9
Genetic variants are known to mediate both pharmacokinetic
and pharmacodynamic processes, thereby playing a major role in
drug response.10 Pharmacogenomics, which evaluates the role of
genetics in drug response, offers a promising avenue for
understanding variation in drug response,11 illuminating novel
pathways, informing drug development and selection,12–14
optimizing dosing regimens15–19 and avoiding ADRs.20–22 QT is
highly heritable (35–40%).23–27 Previous pharmacogenomics
studies of drugs associated with QT prolongation, including
thiazide diuretics, a common anti-hypertensive therapy used by
over a quarter of the United States hypertensive population,28
identified multiple loci associated with anti-hypertensive response
and ADRs.29–34 Furthermore, thiazide diuretics are used unequally
across race/ethnic groups in the United States, with approximately
10% of Hispanic/Latinos, 13% of European Americans, and 23% of
African Americans taking a thiazide diuretic.28,35,36 Therefore, the
pharmacogenomics of thiazide-induced QT prolongation repre-
sents an excellent but understudied candidate for pharmacoge-
nomic inquiry.
We previously examined evidence for common single-
nucleotide polymorphisms (SNPs) that modified the association
between thiazide use and QT and failed to identify any genome-
wide significant loci (Po5 × 10− 8).37 However, our previous study
was limited to European descent populations and cross-sectional
analyses, despite many of the contributing studies having
longitudinal drug and electrocardiographic data.37 Here, we
expand upon that work, applying recent statistical innovations
to leverage longitudinal data and including an additional 44 418
participants of European, African American, and Hispanic/Latino
descent to perform the first trans-ethnic genome-wide association
study (GWAS) to examine genetic associations that modify the
association between thiazides and QT, as well as the component
parts of QT (JT interval (JT), QRS interval (QRS)).
MATERIALS AND METHODS
Study populations
Fourteen cohorts from in the Cohorts for Heart and Aging Research in
Genomic Epidemiology (CHARGE)38 Pharmacogenomics Working Group
(PWG) participated in this analysis, contributing 78 199 participants:
European descent (51 601), African American (11 482), and Hispanic/Latino
(15 116) participants (Table 1; Supplementary Text). Among the fourteen
cohorts, six (55% of the total population) had repeated measurements of
medication use and electrocardiogram (ECG) assessments and contributed
longitudinal data to the analysis: Age, Gene/Environment Susceptibility—
Reykjavik Study (AGES), Atherosclerosis Risk in Communities (ARIC) Study,
Cardiovascular Health Study (CHS), Rotterdam Study (RS), Multi-Ethnic
Study of Atherosclerosis (MESA), and Women’s Health Initiative (WHI). The
remaining eight cohorts contributed cross-sectional data to the analysis:
Framingham Heart Study (FHS), Erasmus Rucphen Family (ERF) Study,
Health 2000 (H2000), Health, Aging, and Body Composition (Health ABC),
Prospective Study of Pravastatin in the Elderly at Risk (PROSPER), Jackson
Heart Study (JHS), Netherlands Epidemiology of Obesity (NEO) Study, and
Hispanic Community Health Study/Study of Latinos (HCHS/SOL).
Study design
Participants with ECG measurements, medication assessment, and
genome-wide genotype data were eligible for inclusion. The following
exclusion criteria were applied: poor ECG quality, atrial fibrillation detected
by ECG, pacemaker implantation, second or third degree atrioventricular
heart block, QRS greater than 120 ms, prevalent heart failure, pregnancy,
missing ECG, missing medication assessment, missing genotype informa-
tion, or race/ethnicity other than European descent, African American, or
Hispanic/Latino. For studies with longitudinal data, exclusion criteria were
applied on a visit-specific basis.
Medication assessment
Medication use was assessed through medication inventories conducted
during clinic visits, home interviews, or through pharmacy databases
(Supplementary Table 1). Six studies captured medication used on the day
of the study visit. A further six of the 14 participating cohorts captured
medications used 1–2 weeks preceding ECG assessment. HCHS/SOL
ascertained medications used within four weeks preceding ECG measure-
ment, and the RS captured medication used within 30 days preceding ECG
assessment. Participants were classified as thiazide diuretic users if they
took a thiazide or thiazide-like diuretic in a single or combination
preparation, with or without potassium (K)-sparing agents, and with or
without K-supplements.
For cross-sectional studies, the number of exposed participants
(Nexposed) was defined as the number of participants classified as thiazide
users. For studies with longitudinal data, Nexposed was calculated as follows:
Nexposed ¼
X
i
ni
1þ ni - 1ð Þρ^
# Eit ¼ 1f g
ni
where ni is the number of observations for participant i, ρ^ is an estimate of
the pairwise visit-to-visit correlation within participants from a Generalized
Estimating Equation (GEE)-exchangeable model that does not contain
genetic data, and #fEit ¼ 1g is the number of observations for which
participant i was exposed.39
ECG interval measurement
QT and QRS were digitally recorded by each participating study using
resting, supine or semi-recumbent, standard 12-lead ECGs (Supplementary
Table 2). Comparable procedures were used for preparing participants,
placing electrodes, recording, transmitting, processing, and controlling
quality of ECGs. Studies used Marquette MAC 5000, MAC 12, MAC 1200 or
MAC PC (GE Healthcare, Milwaukee, Wisconsin, USA), University of Glasgow
(Cardiac Science, Manchester, UK), or ACTA (EASOTE, Florence, Italy)
machines. Recordings were processed using one of the following programs
(Marquette 12SL, MEANS, University of Glasgow, Digital Calipers, or Health
2000 custom-made software. JT was calculated by the formula:
JT =QT–QRS.
Genotyping and imputation
Each study conducted genome-wide genotyping independently using
either Affymetrix (Santa Clara, CA, USA) or Illumina (San Diego, CA, USA)
arrays (Supplementary Table 3). Sex mismatches, duplicate samples, and
first-degree relatives (except in ERF, FHS, HCHS/SOL and JHS) were
excluded. DNA samples with call rates less than 95–98% were excluded, as
were SNPs with SNP call rates less than 90–98%, minor allele frequencies
(MAF) less than 1%, or that failed Hardy-Weinberg equilibrium. To
maximize genome coverage and comparisons across genotyping plat-
forms, genotypes were imputed using HapMap2,40–42 1000 Genomes
Phase 1, or 1000 Genomes Phase 3 reference panels.43,44 Genotypes
imputed using build 37 were lifted over to build 3645,46 to enable
comparisons between imputation platforms and results were restricted to
SNPs present in HapMap2.
Statistical analyses
Genome-wide pharmacogenomic analyses were performed by each cohort
independently across ~ 2.5 million SNPs for QT, QRS, and JT separately.
Drug–SNP interactions were estimated assuming an additive genetic
model, using mixed effect models, GEE, or linear regression with robust
standard errors. The analytic model varied based on study design and the
availability of longitudinal data (Supplementary Table 4). All analyses were
adjusted for age (years), sex when applicable, study site or region, principal
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components of genetic ancestry, visit-specific RR interval (ms), and visit-
specific QT altering medications defined using the University of Arizona
Center for Education and Research on Therapeutics (UAZ CERT)
QT-prolonging drug classification.6 Furthermore, ERF, FHS and HCHS/SOL
incorporated estimates of relatedness into all analyses. Study-specific
results were corrected for genomic inflation (λ).
Previous simulations demonstrated that models using robust standard
errors underestimate the variance of coefficient estimates for SNPs with
low MAFs.39 To account for this underestimation, corrected standard errors
were calculated using a (Student’s) t-reference distribution.39 The degrees
of freedom (df) for the t-reference distribution were estimated using
Satterthwaite’s method.47 When cohorts were unable to implement
Satterthwaite’s method, an approximate df was calculated as twice the
cohort- and SNP-specific product of the SNP imputation quality (range:
0,1), the MAF (range: 0.0,0.50), and Nexposed. Standard errors were then
‘corrected’ by assuming a normal reference distribution that yielded the
t-distribution based P-values from the beta estimates.39 Furthermore,
because simulations demonstrated that corrected standard errors were
unstable when minor allele counts among the exposed were low, a cohort-
specific df filter of 15 was applied across all SNPs.39
For each trait, race-stratified and trans-ethnic betas and corrected
standard errors were combined with inverse-variance weighted meta-
analysis conducted in METAL.48 We used a genome-wide significance
threshold of Po5× 10− 8 and a suggestive threshold of Po5× 10− 6.
However, the assumptions of a fixed-effects meta-analysis do not always
hold between race/ethnicities due to differences in patterns of linkage
disequilibrium (LD) across ancestral populations, potential allelic hetero-
geneity, differences in gene-environment and gene-gene interactions, and
differences in environmental and lifestyle factors.49,50 Therefore, trans-
ethnic meta-analysis was also conducted using the Bayesian MANTRA
approach and a genome-wide threshold of log10(Bayes Factor (BF))46 and
a suggestive threshold of log10(BF)45.
51 Additionally, previous studies
have demonstrated the potential to increase power and detect evidence of
pleiotropy by conducting multi-trait analysis across correlated traits.52,53 To
examine potential pleiotropy across ventricular depolarization and
repolarization, we conducted cross-phenotype meta-analysis combining
t-statistics across QRS and JT using an adaptive sum of powered score
(aSPU) test, which tests for both concordant and discordant associations
across some or all of the included traits.54 The reference distribution for the
aSPU test was calculated using 108 simulations.
Genome-wide significant and suggestive meta-analysis results were
examined for gene or pathway enrichment. Previous work has shown that
it is beneficial to apply multiple methods of gene-set analysis (GSA) when
the underlying etiology of the genetic mechanism is unclear.55–57 We
therefore used two methods of GSA. We performed a multiple regression
gene analysis approach followed by a self-contained GSA using gene-level
regression as implemented in MAGMA.58 Post-meta-analysis P-values were
used as input in the analysis and gene-sets were collected from
Ingenuity,59 Panter,60 KEGG61 and ConsensusPathDB62,63 and restricted to
biologically motivated pathways involved in the following: ion transport
Table 1. Study population characteristics of 25 contributing study populations
Population Nexposed Ntotal QT in ms, mean (s.d.) QRS in ms, mean (s.d.) JT in ms, mean (s.d.) Age in years, mean (s.d.) Female, %
European descent
AGES 435 2256 405 (34) 90 (10) 316 (33) 75 (5) 64.2
ARIC 1449 8567 399 (29) 91 (10) 308 (29) 54 (6) 52.6
CHS 1003 3004 414 (32) 88 (10) 322 (30) 72 (5) 62.5
ERF 29 1792 398 (28) NA NA 48 (14) 59.0
FHS 83 3168 415 (30) 88 (10) 328 (30) 40 (9) 52.5
H2000 104 1973 389 (30) NA NA 50 (11) 52.0
Health ABC 217 1560 414 (32) 90 (11) 324 (32) 74 (3) 49.4
MESA 453 2216 412 (29) 93 (9) 320 (29) 62 (10) 52.1
NEO 609 5366 406 (29) 93 (10) 313 (29) 56 (6) 47.0
PROSPER 1175 4556 414 (36) 94 (11) 320 (35) 75 (3) 47.0
RS I 523 4805 397 (29) 97 (11) 300 (28) 69 (9) 60.2
RS II 161 1889 403 (28) 98 (11) 305 (28) 65 (8) 56.6
RS III 93 1950 401 (26) 98 (11) 304 (26) 56 (6) 54.1
WHI GARNETa 431 1981 401 (29) 86 (9) 315 (29) 66 (7) 100
WHI MOPMAPa 268 1383 402 (30) 86 (8) 316 (30) 63 (7) 100
WHI WHIMSa 1106 5135 401 (30) 86 (9) 315 (29) 68 (6) 100
Summary 8139 51 601
African American
ARIC 916 2169 400 (33) 90 (10) 310 (32) 53 (6) 62.3
CHS 351 666 409 (35) 88 (11) 317 (36) 73 (6) 64.4
Health ABC 268 1151 411 (35) 88 (11) 322 (34) 73 (3) 57.6
JHS 463 1862 410 (32) 92 (10) 319 (30) 50 (12) 60.9
MESA 467 1464 410 (32) 91 (10) 319 (31) 62 (10) 54.4
WHI SHARe 1661 4170 401 (34) 85 (9) 316 (33) 61 (7) 100
Summary 4215 11 482
Hispanic/Latino
HCHS/SOL 941 12 024 416 (28) 91 (10) 325 (29) 46 (14) 59.5
MESA 211 1316 409 (30) 91 (10) 318 (30) 61 (10) 51.8
WHI SHARe 224 1776 401 (30) 86 (9) 316 (30) 60 (6) 100
Summary 1376 15 116
Abbreviations: AGES, Age, Gene/Environment Susceptibility—Reykjavik Study; ARIC, Atherosclerosis Risk in Communities; CHS, Cardiovascular Health Study;
ERF, Erasmus Rucphen Family Study; FHS, Framingham Heart Study; GARNET, Genome-wide Association Research Network into Effects of Treatment; HCHS/
SOL, Hispanic Community Health Study/Study of Latinos; Health ABC, Health, Aging, and Body Composition Study; JHS, Jackson Heart Study; JT, JT interval;
MESA, Multi-Ethnic Study of Atherosclerosis; MOPMAP, Modification of Particulate Matter-Mediated Arrhythmogenesis in Populations; NEO, the Netherlands
Epidemiology of Obesity; Nexposed, Number of participants exposed to thiazides; Ntotal, Total number of participants in study population after exclusions;
PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; QRS, QRS interval; QT, QT interval; RS, Rotterdam Study; SHARe, The SNP Health Association
Resource; WHI, Women’s Health Initiative; WHIMS, the WHI Memory Study. aParticipants overlapping between GARNET, MOPMAP and WHIMS were excluded
from analyses to prevent lack of independence.
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and homeostasis, transcription and translation, renal and cardiac devel-
opment and function, and pharmacokinetic/dynamic pathways. Addition-
ally, we selected all SNPs with Po1 × 10− 5 for analysis with DEPICT, which
searches for gene, gene-set and tissue enrichment among 14 461
reconstituted gene-sets, eliminating the need to select candidate gene-
sets.64 To account for multiple testing, we applied a false discovery rate
(FDR) threshold of 5% for both GSA approaches.
Statistical power simulations
Statistical power to detect drug–SNP interactions using cross-sectional and
longitudinal modeling approaches was estimated via simulation studies.
Assumptions, which were informed by European ancestry populations,
included: (1) 50 000 participants; (2) a two-sided, per-SNP α=5× 10− 8; (3) a
mean heart rate-corrected QT (standard deviation) = 400 (30) ms; (4)
Nexposed = 8100; (5) a mean drug effect for those with zero copies of the
minor allele = 5 ms; (6) a mean SNP effect for those not exposed to
drug= 0 ms; (7) a MAF= 0.05 or 0.25; (8) an additive model of inheritance;
(9) two study visits for longitudinal simulations; (10) within-person QT
correlation = 0.80; (11) an attrition rate between visits for longitudinal
simulations = 0.13; (12) random missingness rate across study visits = 0.09;
and (13) an independent GEE correlation structure for longitudinal
simulations. For longitudinal simulations, drug use was either temporally
constant or variable. When variable, drug exposure was assumed to be
completely random at both visits.
RESULTS
Study characteristics
A total of 78 199 participants were included in the analysis, of
which 13 730 (18%) were exposed to thiazides (Table 1). Thiazide
use was most common among African Americans (36%),
compared with 16% and 9% among European descent and
Hispanic/Latino populations, respectively. Mean age ranged from
40 (FHS) to 75 years (PROSPER) and the percentage of females
ranged from 47% (NEO, PROSPER) to 100% (WHI). Average QT was
between 389 ms (H2000) and 416 ms (HCHS/SOL).
Genome-wide analysis of thiazide–SNP interaction and QT interval
Q-Q plots for individual study results, as well as for meta-analyzed
results, demonstrated adequate calibration of study-specific test
statistics (Supplementary Figures 1–4). However, the family-based
studies (ERF, FHS, HCHS/SOL) showed modest evidence of
over-dispersion (λ= 1.07–1.16).
No genome-wide significant thiazide–SNP interaction effects
were detected in any race/ethnic group (Figure 1). However,
suggestive interaction effects (Po5 × 10− 6) were found for 22 loci
in at least one race/ethnic group: European descent (seven loci),
African American (six loci), Hispanic/Latino (six loci), or trans-ethnic
(nine loci) (Figure 1; Table 2). Only the DNAH8/BTBD9 locus was
suggestively significant in more than one race/ethnic group
(rs862433 in African Americans, rs1950398 in Hispanic/Latinos).
Only two of the suggestive SNPs were heterogeneous across
populations with Pheto0.05 (rs4890550 and rs13223427).
Additionally, examination of 35 loci previously associated with
QT in a published main effects GWAS65 found no significant
associations in European descent populations using a Bonferroni
corrected threshold of Po0.001 (0.001 = 0.05/35; Supplementary
Table 5). The magnitude of the interaction effect was close to zero
for all but six of the 35 SNP, which had interaction effects greater
than 0.50 ms.
Similarly, while no locus showed genome-wide significance in
our trans-ethnic MANTRA analysis (Supplementary Figure 5), one
SNP (rs2765279) was above the suggestive threshold, with a
log10(BF) of 5.2. Rs2765279, located in RGSL1, a gene involved in
G-protein signaling regulation, was also the most significant SNP
in the fixed-effects trans-ethnic analysis (P= 3× 10− 7).
Genome-wide analysis of thiazide–SNP interaction and QRS
interval or JT interval
Results for QRS showed a similar pattern to those for QT
(Supplementary Figure 6 and Supplementary Table 6). Whereas
no results achieved genome-wide significance, 28 loci showed
suggestive evidence of modifying the thiazide-QRS association
(four loci in European descent populations, 11 in African
Americans, eight in Hispanic/Latinos, and seven in trans-ethnic
populations) and only one SNP had a Pheto0.05 (rs11591185). The
most significant SNP, rs7638855 (P= 2× 10− 7), located upstream
from GAP43, was also suggestively significant after trans-ethnic
analysis in MANTRA (log10(BF) = 5.4; Supplementary Figure 5).
Similarly, no SNPs showed genome-wide significant interaction
for JT, although 19 loci were suggestively associated (five loci in
European descent populations, four in African Americans, five in
Hispanic/Latino, and seven in trans-ethnic populations;
Supplementary Figure 6 and Supplementary Table 7). No SNPs
showed significant heterogeneity between populations. Moreover,
MANTRA analysis identified two SNPs that achieved suggestive
significance (Supplementary Figure 5). The rs1264878 variant near
KCNIP4, a voltage-gated potassium channel interacting protein
was the most significant SNP in our fixed-effects meta-analyses
(P= 3× 10− 7) and had a log10(BF) = 5.1. However, most significant
SNP in MANTRA meta-analyses was rs9303589, in CA10, with a
log10(BF) = 5.1.
Cross-phenotype meta-analysis
Cross-phenotype meta-analysis found no genome-wide significant
evidence of pleiotropy across QRS and JT (Figure 2 and
Supplementary Figure 7). However, eight loci had a suggestive
evidence of thiazide–SNP interaction after meta-analyzing QRS
and JT results (Table 3). These included three loci that were
nominally associated with QRS and JT (Po0.05), but whose effects
did not reach the suggestive association threshold in either
univariate analysis (rs1295230 [PIK3R6], rs6931354 [ADGRB3] and
rs8119517 [PREX1]).
Gene and pathway enrichment analysis
Although analysis with DEPICT found no enrichment in a single
gene or tissue, gene-set enrichment analysis in European descent
populations found enrichment in the ATXN3 subnetwork for the
interactive effect of genotype and thiazide use on QT
(P= 1 × 10− 6). There was no enrichment found in QRS or JT
analyses. MAGMA analyses found significant enrichment in six
genes among African Americans in the interactive effect of
genotype and thiazide use on QRS: CNTRL, CPN1, FAM65B, RAB14,
ISY1, NELL1 (Supplementary Table 8). No other MAGMA analyses
found gene enrichment. MAGMA GSA for QT and JT analyses
found significant enrichment for transcription and translational
pathways, although no gene-set enrichment was found in QRS
analyses (Table 4).
Statistical power
Given the biologic plausibility of the suggestive results for all three
traits, we examined statistical power for our analysis to assess our
ability to detect interaction effects. Simulations demonstrated that
all analyses were underpowered to detect thiazide–SNP interac-
tion effects less than 3 ms (e.g. 15% power to detect an interactive
effect of 2 ms; Figure 3). However, even with time-varying drug
exposure (that is, observed QT measurement on and off drug
within an individual), which demonstrated the greatest power,
analyses for SNPs with MAF= 5% did not achieve 80% power until
the thiazide–SNP interaction effect reached 6 ms.
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DISCUSSION
In this study, we examined 78 199 participants of European,
African American or Hispanic/Latino descent for evidence of
thiazide–SNP interactions influencing QT. Although we used a
comprehensive approach that considered multi-ethnic
populations, leveraged pleiotropy, accommodated population
Figure 1. Manhattan plots of P-values for thiazide–SNP (single-nucleotide polymorphism) interaction estimates for QT interval analyses after
fixed-effects meta-analysis among European descent populations (N= 51 601), African American populations (N= 11 482), Hispanic/Latino
populations (N= 15 116), and all populations (trans-ethnic). Each study was analyzed using linear regression, mixed-effects models, or
generalized estimating equations and SNPs with a study-specific degree of freedom measure (df= twice the cohort- and SNP-specific product
of the SNP imputation quality (range: 0,1), the MAF (range: 0.0,0.50), and the number of individuals exposed to thiazide (Nexposed))o15 were
excluded from meta-analysis. The x-axis represents the chromosomal position and the y-axis represents the –log10(P-value). On each plot,
genome-wide significance (Po5x10− 8) and suggestive significance (Po5x10− 6) are denoted with dashed lines.
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heterogeneity, and examined QT as well as its component parts
(QRS, JT), we did not identify any genome-wide significant SNPs
modifying the association between thiazides and these ECG
intervals. However, we identified 74 loci with suggestive evidence
of association through either univariate or cross-phenotype
analyses as well as evidence of enrichment in pathways involved
in transcription and translation.
Interestingly, our suggestive results included multiple loci
involved in ion transport and handling, the disruption of which
is believed to be an underlying mechanism in drug-induced QT
prolongation,66 supporting the hypothesis that common SNPs
modify the thiazide-QT relationship. For example, the NELL1 locus
was previously associated with changes in fasting plasma
triglyceride levels in response to hydrochlorothiazide use.67 Other
interesting suggestive results include the PITX2 and RYR3
QRS loci identified in Hispanic/Latinos, which may directly regulate
ion channel genes and genes involved in calcium handling.68
Moreover, we found suggestive evidence of thiazide–SNP inter-
actions on QT, QRS, or JT in other genes involved in ion transport
and handling, including STC2,69 EDN1,70 TRPC7,71 PKP272 and
DISC1,73 as well as a voltage-gated potassium channel gene
(KCNQ3).
Despite these intriguing results, our power simulations
suggested there was limited power to detect interaction effects
of 2 ms, sizes consistent with QT main effects analyses.65 The low
power suggests that larger sample sizes and/or innovative
statistical methods may be required to study gene-environment
interactions given the stringent genome-wide significance
threshold.74–76 Furthermore, our power simulations demonstrated
insufficient power to detect interaction effects of 5 ms or less for
less common SNPs (MAF= 5%). Therefore, future work should
utilize larger sample sizes, particularly studies with longitudinal
data, if available.
Another limitation of our work was that medication use data
were collected infrequently, e.g. years apart. Particularly, medica-
tion assessments covered only one to two weeks of medication
use in most participating cohorts and variables such as medication
dosage and duration of use were not available universally across
studies. Previous work has demonstrated a dose-dependent
relationship between thiazide use and cardiac arrest, a potential
outcome of QT prolongation.77 However, we were unable to
identify participants using high dose thiazides because medica-
tion dosage data was unavailable in all cohorts. Furthermore, K+
measurements and information on K+ supplements was not
obtained across all cohorts so we were unable to adjust for K+
levels in our analyses, despite the known role of thiazide diuretics
in inducing hypokalemia and the role of hypokalemia in causing
QT prolongation.78,79
Furthermore, ECG intervals are known to vary in the presence of
cardiovascular disease (CVD).80 While we did exclude participants
with certain types of CVD including prevalent heart failure and
atrial fibrillation, we were not able to further characterize the role
Table 2. Loci with suggestive evidence of association with the thiazide–SNP interaction effect on QT interval
Locus SNP Chr Positiona CA CAF Interaction effect in ms (s.e.) P-value Phet
European descent
KIAA2013 rs17367934 1 11890791 A 0.89 2.4 (0.5) 2 × 10− 6 0.9
SLC14A2 rs4890550 18 41409189 C 0.44 − 1.4 (0.3) 3 × 10− 6 0.01
RPS29 rs10143493 14 47999650 A 0.01 − 10.6 (2.3) 3 × 10− 6 0.4
NELL1 rs12225793 11 21057283 T 0.12 2.3 (0.5) 4 × 10− 6 1.0
STC2 rs10079004 5 172704698 A 0.71 − 1.5 (0.3) 4 × 10− 6 0.4
LCLAT1 rs7608507 2 30447424 A 0.75 1.6 (0.3) 4 × 10− 6 0.7
PPP1R3A rs13223427 7 113199332 T 0.56 1.4 (0.3) 4 × 10− 6 0.02
African American
ZBTB16 rs10789991 11 113424299 T 0.03 12.3 (2.4) 5 × 10− 7 0.6
DNAH8 rs862433 6 38968057 A 0.25 − 2.6 (0.5) 7 × 10− 7 0.2
Intergenic rs9376483 6 140352934 T 0.94 7.2 (1.4) 7 × 10− 7 0.5
CASP8AP2 rs7753194 6 90597484 A 0.02 − 11.4 (2.4) 3 × 10− 6 0.2
EBF1 rs11135035 5 157833407 A 0.41 2.1 (0.5) 4 × 10− 6 0.9
LAMA4 rs6926485 6 112630302 T 0.64 2.4 (0.5) 5 × 10− 6 0.5
Hispanic/Latino
SPDYA rs12475612 2 28883510 T 0.48 − 3.5 (0.7) 1 × 10− 6 0.9
BTBD9 rs1950398 6 38666897 T 0.97 9.6 (2.0) 2 × 10− 6 0.05
TDRP rs6558894 8 480495 C 0.14 − 4.9 (1.0) 2 × 10− 6 0.3
COLCA2 rs10749974 11 110696967 A 0.09 − 6.0 (1.3) 3 × 10− 6 0.2
CRYGGP rs17868255 2 51884417 A 0.97 10.3 (2.2) 3 × 10− 6 0.5
RYR3 rs16968694 15 31376213 A 0.18 4.5 (1.0) 3 × 10− 6 1.0
Trans-Ethnic
RGSL1 rs2765279 1 180693520 T 0.28 1.4 (0.3) 3 × 10− 7 0.4
ZBTB16 rs10789991 11 113424299 T 0.03 12.3 (2.4) 5 × 10− 7 0.6
PPP1R3A rs17619887 7 113142601 A 0.47 1.2 (0.3) 2 × 10− 6 0.07
KIAA2013 rs17367934 1 11890791 A 0.89 2.3 (0.5) 2 × 10− 6 1.0
LCLAT1 rs6756908 2 30446501 A 0.65 1.3 (0.3) 2 × 10− 6 0.5
FAR1 rs7130476 11 13711632 C 0.90 2.0 (0.4) 3 × 10− 6 0.5
CASP8AP2 rs7753194 6 90597484 A 0.02 − 11.4 (2.4) 3 × 10− 6 0.2
SMARCA2 rs1886261 9 2163590 A 0.75 1.5 (0.3) 3 × 10− 6 0.9
ZKSCAN8 rs13205911 6 28232093 T 0.09 − 2.5 (0.5) 5 × 10− 6 0.6
Abbreviations: CA, coded allele; CAF, coded allele frequency; Chr, chromosome; Phet, P-value of heterogeneity; SNP, single-nucleotide polymorphism.
aBuild 36
base-pair position.
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of CVD in the pharmacogenomics of thiazide use and QT duration.
Given that we saw larger mean QT and JT intervals in Hispanic/
Latino populations than in European descent or African American
populations in our study sample, as well a substantial difference in
mean exposure to thiazides, ranging from just 9% in Hispanic/
Latinos to 37% in African Americans, our analyses are limited by
the heterogeneity of exposure and outcome in our population.
The large difference in thiazide exposure between race/ethnic
groups could also indicate an underlying difference in CVD
prevalence among our populations. Considering that pharmaco-
genomic studies such as this one are already limited in their
power to detect effects, the addition of unmeasured hetero-
geneity such as CVD status could further reduce our power to
detect genetic effects modifying the relationship between
thiazides and QT. Therefore, future work should consider alternate
study designs, such as clinical trials or specially collected cohorts,
as settings for pharmacogenomics work. In clinical trials or
specialty cohorts, populations can be more closely controlled
and therefore more homogeneous in traits that may confound the
relationship between thiazides and QT.
Additionally, observational cohort studies are known to be
susceptible to selection biases, such as prevalent user bias,
whereby long-term medication users are least likely to suffer from
ADRs and users with ADRs often stop therapy and therefore have
a lower chance of being seen while on therapy.81,82 Unfortunately,
without information on duration of use, it is difficult to evaluate
the effect of prevalent user bias on study results. Indeed, it is
unclear if these biases are of concern in pharmacogenomic
studies.83,84 Additional work is needed to assess whether selection
bias requires more consideration in pharmacogenomic research
and to assess possible advantages of alternative designs,
such as active comparator designs (whereby the control group
contains participants using a different class of medications with
similar indications to the medication of interest) or new user
Figure 2. Manhattan plots of P-values thiazide–SNP interaction estimates after cross-phenotype meta-analysis (QRS interval, JT interval) using
aSPU among European descent populations (N= 47 836), African American populations (N= 11 482), and Hispanic/Latino populations
(15 116). For each trait separately, each study was analyzed using linear regression, mixed-effects models, or generalized estimating equations
and SNPs with a study-specific degree of freedom measure (df= twice the cohort- and SNP-specific product of the SNP imputation quality
(range: 0,1), the MAF (range: 0.0,0.50), and the number of individuals exposed to thiazide (Nexposed))o15 were excluded from cross-phenotype
meta-analysis. The x-axis represents the chromosomal position and the y-axis represents the –log10(P-value). On each plot, genome-wide
significance (Po5x10− 8) and suggestive significance (Po5x10− 6) are denoted with dashed lines.
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designs (whereby prevalent users are excluded). Moreover,
medication inventories may be associated with non-negligible
measurement error. For example, while Smith et al. reported good
agreement between thiazide use measured using medication
inventories and serum thiazide measurements, specificity
remained moderate.85
Given the challenges associated with assembling an adequately
powered pharmacogenomics study, electronic medical records
(EMRs) represent a potential untapped resource that may merit
evaluation. Strengths of EMRs include the potential to provide a
more complete medication history, which could enable sensitivity
analyses examining variables such as medication dose and
duration of use. Furthermore, consortia such as eMERGE have
demonstrated the feasibility of linking EMRs to genetic data for
use in genetic research,86 and have successfully identified genetic
variants modifying drug response.87 However, EMRs have limita-
tions. Investigators using EMR data cannot control participant
recruitment, timing and accuracy of data collection, or population
representativeness.88 Considering ECG research specifically, cohort
studies administer ECGs to all participants at study visits, whereas
EMRs may capture ECGs for patients with medical indications,
providing an inherently different population. EMRs therefore have
the potential to greatly advance pharmacogenomic research but
warrant further evaluation.
In conclusion, our findings suggest that additional work is
needed to fully elucidate potential pharmacogenomic effects
influencing the thiazide-QT relationship. Our suggestive results
support a possible role of genetics in modifying the association
between thiazides and QT. However, these findings can inform the
biology of thiazide-induced QT prolongation and do not preclude
the possibility of common variants with small effects or rare
variants with larger effects. Future work that leverages larger
sample sizes, such as those available in EMRs, and innovative
statistical methods to validate these suggestive findings is
needed. The FDA considers further regulation of drugs that
prolong QT by as little as 5 ms, a small increment easily
achieved by the combination of genetic and pharmaceutical
effects,37,89 making it critical that we unravel the complex
etiology of drug-induced QT prolongation.90 Pharmacogenomics
remain a promising avenue for understanding variability in drug
Table 4. Gene-sets with enrichment for genotype–thiazide interaction effects
Trait Population Gene-set P-value FDR
QT Hispanic/Latino Nucleotide Binding 5 ×10− 6 0.004
Metal Ion Binding 6 ×10− 6 0.004
tRNA Adenine-N1 Methyltransferase Activity 6 × 10− 5 0.03
Transcription Coactivator Activity 8 × 10− 5 0.03
Transcriptional Activity of SMAD2, SMAD3, SMAD4, Heterotrimer 0.0001 0.03
Zinc Ion Binding 0.0002 0.04
Other RNA Binding Protein 0.0002 0.04
Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPS/IMPS/VICKZS) 0.0003 0.05
Trans-Ethnic General RNA Polymerase II Transcription 4 × 10− 6 0.006
Transcription 4 × 10− 5 0.03
JT African American Transcription Factor TFIID Complex 7 × 10− 5 0.05
Aminoacyl-tRNA Synthetase Multienzyme Complex 0.0001 0.05
tRNA Aminoacylation for Protein Translation 0.0001 0.05
Transcription Factor TFTC Complex 0.0001 0.05
Trans-Ethnic Transciption 3 × 10− 5 0.03
General RNA Polymerase II Transcription Factor Activity 4 × 10−5 0.03
Abbreviations: FDR, false discovery rate; JT, JT interval; QT, QT interval.
Table 3. Loci with suggestive evidence modifying the effect of Thiazide on QRS and JT intervals after cross-phenotype meta-analysis
Locus SNP Chr Positiona CA CAF P-value Univariate P-value
QRS JT
European descent
PIK3R6 rs1295230 17 8682305 T 0.02 3 × 10− 6 0.008 0.001
African American
ADGRB3 rs6931354 6 69527128 A 0.21 1 × 10− 7 0.005 0.0002
ADCY8 rs10108730 8 131767803 T 0.79 2 × 10− 6 1 × 10− 5 0.0003
PREX1 rs8119517 20 46464282 A 0.94 3 × 10− 6 0.0005 0.02
CDH13 rs11649358 16 81415652 A 0.75 5 × 10− 6 9x10− 6 0.001
Hispanic/Latino
AK2 rs11591185 1 33274771 A 0.07 2 × 10− 6 7 × 10− 7 3 × 10− 5
ASS1P14 rs12578228 12 33030528 T 0.10 2 × 10− 6 2 × 10− 6 2 × 10− 5
GALNT13 rs17553946 2 155055407 A 0.23 4 × 10− 6 0.005 9× 10− 7
Abbreviations: CA, coded allele; CAF, coded allele frequency; Chr, chromosome; JT, JT interval; QRS, QRS interval; SNP, single-nucleotide polymorphism. aBuild
36 base-pair position.
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response and for utilizing genetics to improve public health
but innovative solutions are needed to overcome inherent
challenges.
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